Clearant Gains Support for Clearant Process(R) Sterile Implants at the American Orthopaedic Society for Sports Medicine Annual Conference; Medical Conference Generates Surgeons Interest in Converting to Clearant Process Sterile Implants.

LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced that it received a groundswell of interest from orthopedic surgeons considering using sterile allograft implants in their practices during the recent American Orthopaedic Society for Sports Medicine (AOSSM) annual meeting in Hershey, Pennsylvania. E[acute accent]"More than 50 surgeons attending the AOSSM annual meeting requested that we follow up to provide information and assistance on potentially converting their practices to the use of Clearant Process sterile implants," said Chief Executive Officer Alain Delongchamp. E[acute accent]Clearant-sponsored an educational symposium featuring presentations by leading surgeons on the benefits of using Clearant Process implants. A panel of leading orthopaedic surgeons included: Dr. Phil Davidson of Tampa Bay Orthopaedic Specialists, Dr. Ty Endean of the Sports Institute of Tucson, and Dr. Chris Larson of Allina Medical Group of Minnesota. E[acute accent]"...Patient outcomes with Clearant processed sterile grafts show a range of motion following surgery which are statistically equivalent to commercially available non-sterile processed grafts..." said Dr. Phil Davidson, Tampa Bay Orthopaedic Specialists, and a participant in the Clearant multi center patient follow up study. E[acute accent]Dr. Ty Endean, Sports Institute of Tucson, added that "...the biomechanical property of tissue sterilized by the Clearant Process, which provides robust viral inactivation of HIV, has comparable strength to non-sterile grafts." Dr Endean is also a current user of Clearant Process sterile sports medicine implants. E[acute accent]"We are very pleased with the positive response Clearant received at the AOSSM conference. In addition to our sales force initiative, Clearant's participation in major orthopedic specialty conventions and meetings is a key part of our company's direct distribution strategy," said Clearant Chief Executive Officer Alain Delongchamp. "Based on the response at AOSSM, a growing number of surgeons are potentially converting their practices to the use of Clearant Process sterile implants."

E[acute accent]About Clearant, Inc.

E[acute accent]Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

E[acute accent]Forward-Looking Statements

E[acute accent]Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, acceptance and success of our direct distribution of allografts, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.